Arcutis Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2830 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Mar 12th, 2025 1:40 pm
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - Mar 7th, 2025 1:00 pm
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Mar 6th, 2025 2:30 pm
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 5th, 2025 9:00 pm
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Mar 5th, 2025 2:55 pm
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - Feb 28th, 2025 2:00 pm
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? - Feb 28th, 2025 11:37 am
Arcutis Biotherapeutics Full Year 2024 Earnings: Beats Expectations - Feb 27th, 2025 11:35 am
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis - Feb 26th, 2025 1:00 pm
Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Feb 26th, 2025 7:15 am
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates - Feb 25th, 2025 10:10 pm
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Feb 25th, 2025 9:00 pm
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology - Feb 24th, 2025 1:00 pm
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Feb 20th, 2025 3:00 pm
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference - Feb 18th, 2025 9:35 pm
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet - Feb 17th, 2025 2:55 pm
High Growth Tech Stocks To Watch In February 2025 - Feb 17th, 2025 2:02 pm
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates - Feb 13th, 2025 10:10 pm
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - Feb 13th, 2025 3:18 pm
Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher - Feb 11th, 2025 2:55 pm